294 related articles for article (PubMed ID: 32027513)
1. Surface Stabilization and Dissolution Rate Improvement of Amorphous Compacts with Thin Polymer Coatings: Can We Have It All?
Novakovic D; Peltonen L; Isomäki A; Fraser-Miller SJ; Nielsen LH; Laaksonen T; Strachan CJ
Mol Pharm; 2020 Apr; 17(4):1248-1260. PubMed ID: 32027513
[TBL] [Abstract][Full Text] [Related]
2. Polymer Nanocoating of Amorphous Drugs for Improving Stability, Dissolution, Powder Flow, and Tabletability: The Case of Chitosan-Coated Indomethacin.
Li Y; Yu J; Hu S; Chen Z; Sacchetti M; Sun CC; Yu L
Mol Pharm; 2019 Mar; 16(3):1305-1311. PubMed ID: 30668120
[TBL] [Abstract][Full Text] [Related]
3. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
Saboo S; Kestur US; Flaherty DP; Taylor LS
Mol Pharm; 2020 Apr; 17(4):1261-1275. PubMed ID: 32134677
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Surface Crystallization and Improving Dissolution of Amorphous Loratadine by Dextran Sulfate Nanocoating.
Zeng A; Yao X; Gui Y; Li Y; Jones KJ; Yu L
J Pharm Sci; 2019 Jul; 108(7):2391-2396. PubMed ID: 30831122
[TBL] [Abstract][Full Text] [Related]
6. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
[TBL] [Abstract][Full Text] [Related]
7. Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.
Petry I; Löbmann K; Grohganz H; Rades T; Leopold CS
Eur J Pharm Biopharm; 2017 Oct; 119():150-160. PubMed ID: 28602869
[TBL] [Abstract][Full Text] [Related]
8. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
Baghel S; Cathcart H; O'Reilly NJ
Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
[TBL] [Abstract][Full Text] [Related]
9. Improving Stability and Dissolution of Amorphous Clofazimine by Polymer Nano-Coating.
Gui Y; Chen Y; Chen Z; Jones KJ; Yu L
Pharm Res; 2019 Mar; 36(5):67. PubMed ID: 30877389
[TBL] [Abstract][Full Text] [Related]
10. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
[TBL] [Abstract][Full Text] [Related]
11. Understanding Dissolution and Crystallization with Imaging: A Surface Point of View.
Novakovic D; Isomäki A; Pleunis B; Fraser-Miller SJ; Peltonen L; Laaksonen T; Strachan CJ
Mol Pharm; 2018 Nov; 15(11):5361-5373. PubMed ID: 30247922
[TBL] [Abstract][Full Text] [Related]
12. Emerging trends in the stabilization of amorphous drugs.
Laitinen R; Löbmann K; Strachan CJ; Grohganz H; Rades T
Int J Pharm; 2013 Aug; 453(1):65-79. PubMed ID: 22569230
[TBL] [Abstract][Full Text] [Related]
13. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
Qian F; Huang J; Hussain MA
J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
[TBL] [Abstract][Full Text] [Related]
14. Refining stability and dissolution rate of amorphous drug formulations.
Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
[TBL] [Abstract][Full Text] [Related]
15. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
Meng F; Gala U; Chauhan H
Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Physical Stability of Amorphous Drug Formulations via Dry Polymer Coating.
Capece M; Davé R
J Pharm Sci; 2015 Jun; 104(6):2076-2084. PubMed ID: 25902736
[TBL] [Abstract][Full Text] [Related]
17. Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy.
Rautaniemi K; Vuorimaa-Laukkanen E; Strachan CJ; Laaksonen T
Mol Pharm; 2018 May; 15(5):1964-1971. PubMed ID: 29584954
[TBL] [Abstract][Full Text] [Related]
18. Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Case of Clofazimine and Poly(acrylic acid).
Gui Y; McCann EC; Yao X; Li Y; Jones KJ; Yu L
Mol Pharm; 2021 Mar; 18(3):1364-1372. PubMed ID: 33522821
[TBL] [Abstract][Full Text] [Related]
19. Analytical and Computational Methods for the Determination of Drug-Polymer Solubility and Miscibility.
Thakore SD; Akhtar J; Jain R; Paudel A; Bansal AK
Mol Pharm; 2021 Aug; 18(8):2835-2866. PubMed ID: 34041914
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.
Ricarte RG; Van Zee NJ; Li Z; Johnson LM; Lodge TP; Hillmyer MA
Mol Pharm; 2019 Oct; 16(10):4089-4103. PubMed ID: 31487183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
